Clinical evaluation of immunoinhibition determination of creatine kinase B subunits in coronary care.

Development and clinical evaluation of a microcentrifugal analyzer method for determining creatine kinase MB isoenzyme.

We have adapted to a microcentrifugal analyzer an immunoinhibition assay for measuring the activity of creatine kinase MB by using an inhibitory antibody for the M monomer. The method actually measures half the MB activity, but results are not multiplied by two because atypical isoenzymes of creatine kinase, including BB, IgG-BB, and the isoenzyme derived from mitochondria, are also detected, i...

Clinical and analytical evaluation of kits for measurement of creatine kinase isoenzyme MB.

We studied the analytical and clinical performance of six methods for creatine kinase (EC 2.7.3.2) isoenzyme MB (CK-MB): three immunoassays (Behring, Hybritech, and International Immunoassay Labs); one immunoinhibition assay (Roche); one immunoinhibition/column method (Du Pont); and one electrophoretic method (Beckman). Between-day precision for all kits was poor at the upper reference limit. A...

Creatine kinase isoenzyme MB determination on the ACA: dependence on serum matrix and other effectors.

Creatine kinase isoenzyme MB catalytic activities in human serum, determined by ACA ion exchange chromatography and immunoinhibition, differ significantly, the correlation coefficient being 0.88. The reasons for this variation are interference of antibodies with the creatine kinase B subunit in the immunoinhibition assay, nonreproducible elution of creatine kinase isoenzyme MB from the ion exch...

Direct reaction-rate determination of creatine kinase isoenzyme MB with a centrifugal analyzer, based on immunoinhibition.

An immunoinhibition assay for determination of creatine kinase isoforms in serum.

We report a preliminary evaluation of an immunoinhibition assay for creatine kinase isoform quantification. The procedure employs the monoclonal antibody CKM-G01, which inhibits the native M subunit of creatine kinase. The antibody does not inhibit the M subunit modified by removal of lysine by plasma carboxypeptidase N. Residual activity after treatment with the antibody is therefore due to se...